Suggested Remit: To appraise the clinical and cost effectiveness of pembrolizumab within its marketing authorisation for previously treated oesophageal or gastro-oesophageal junction cancer.
Appraisal suspended
 
Status Suspended
Process STA 2018
ID number 1357

Email enquiries

Consultees

Companies sponsors Merck Sharp & Dohme (pembrolizumab)
Others Department for Health and Social Care
  NHS England
  Welsh Government
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Accord Healthcare (docetaxel, paclitaxel, irinotecan) (not signed confidentiality agreement)
  Actavis UK (docetaxel, paclitaxel, irinotecan) (not signed confidentiality agreement)
  Celgene (paclitaxel) (not signed confidentiality agreement)
  Hospira UK (docetaxel, paclitaxel, irinotecan) (not signed confidentiality agreement)
  Medac GmbH (docetaxel, paclitaxel, irinotecan) (not signed confidentiality agreement)
  Pfizer Ltd (irinotecan) (not signed confidentiality agreement)
  Sanofi (docetaxel) (not signed confidentiality agreement)
  Seacross Pharmaceuticals (docetaxel, irinotecan) (not signed confidentiality agreement)
  Shire Pharmaceuticals (irinotecan) (not signed confidentiality agreement)
General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research
  National Cancer Research Institute

Timeline

Key events during the development of the guidance:

Date Update
16 September 2019 The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps.
11 April 2019 Suspended, Appraisal suspended
07 March 2019 Invitation to participate
04 April 2018 - 02 May 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
01 March 2017 In progress, DH Referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance